GC
VBIV

Grimes & Company’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Grimes & Company’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,768
Closed -$88.8K – 325
2023
Q1 		$88.8K Buy
9,768
+89
+0.9% +$1.26K ﹤0.01% 285
2022
Q4 		$114K Buy
9,679
+49
+0.5% +$864 ﹤0.01% 277
2022
Q3 		$204K Buy
9,630
+116
+1% +$3.13K 0.01% 253
2022
Q2 		$231K Buy
9,514
+145
+2% +$4.93K 0.01% 247
2022
Q1 		$467K Buy
9,369
+1,537
+20% +$75.9K 0.02% 204
2021
Q4 		$550K Sell
7,832
-767
-9% -$64.6K 0.03% 195
2021
Q3 		$802K Buy
8,599
+543
+7% +$51.6K 0.03% 169
2021
Q2 		$810K Buy
8,056
+560
+7% +$54.6K 0.04% 166
2021
Q1 		$699K Buy
7,496
+2,799
+60% +$284K 0.03% 169
2020
Q4 		$388K Buy
4,697
+121
+3% +$10.3K 0.02% 202
2020
Q3 		$393K Buy
4,576
+22
+0.5% +$2.56K 0.03% 190
2020
Q2 		$424K Buy
4,554
+1,183
+35% +$65.2K 0.03% 185
2020
Q1 		$96K Buy
3,371
+714
+27% +$27.8K 0.01% 221
2019
Q4 		$110K Buy
+2,657
New +$58.2K 0.01% 259

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Grimes & Company's VBIV Position: Q2 2023 in Review

Grimes & Company sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 9,768 shares — an estimated $88.8K sold.

Grimes & Company first reported a position in VBIV in Q4 2019 and held it in 14 quarters. The position peaked at $810K in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Grimes & Company reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Grimes & Company sold 9,768 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $88.8K.
  • Grimes & Company first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 14 quarters.
  • Grimes & Company's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $810K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Grimes & Company's 13F filing for Q2 2023, filed 19 Jul 2023.